PTC Therapeutics Reports Q2 2025 Revenue of $178.9 Million, Net Income Turnaround

PTC Therapeutics, Inc. reported its financial results for the second quarter of 2025, revealing a total revenue of $178.9 million, a decrease of 4% from $186.7 million in the same period last year. The decline was primarily driven by a drop in net product revenue, which fell to $118.3 million from $133.2 million, largely due to decreased sales of its key products, Emflaza and Translarna. Emflaza's revenue decreased by 23% to $36.4 million, while Translarna's revenue dropped by 15% to $59.5 million, attributed to increased generic competition and regulatory challenges in the European market.

In contrast, collaboration and license revenue surged to $2.9 million, reflecting the impact of a $1 billion upfront payment from Novartis as part of a licensing agreement related to PTC's votoplam program. Royalty revenue also increased by 8% to $57.6 million, driven by higher sales of Evrysdi, a product developed in collaboration with Roche. The company's total operating expenses for the quarter were $213.8 million, down from $226.9 million a year earlier, with significant reductions in research and development costs, which fell to $113.0 million from $132.2 million.

PTC's financial position improved significantly, with cash and cash equivalents totaling $1.02 billion as of June 30, 2025, compared to $779.7 million at the end of 2024. The company also reported a net income of $801.7 million for the first half of 2025, a stark contrast to a net loss of $190.8 million for the same period in 2024. This turnaround was largely due to the recognition of substantial collaboration revenue from the Novartis agreement.

Operationally, PTC Therapeutics has made strides in expanding its product offerings. The FDA approved Sephience for the treatment of phenylketonuria (PKU) on July 28, 2025, and the company is pursuing additional regulatory approvals in Brazil and Japan. The company also continues to focus on its gene therapy products, with Upstaza receiving approvals in the European market and Kebilidi being approved by the FDA for AADC deficiency.

Looking ahead, PTC Therapeutics anticipates ongoing expenses related to commercialization efforts and clinical trials. The company expects to continue investing in its product pipeline while navigating the complexities of pricing and reimbursement negotiations in various markets. Despite the challenges, PTC remains optimistic about its financial outlook, bolstered by its strong cash position and recent product approvals.